Blockade of a Laminin-411–Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk

Gliomas often progress from low to high grade, and are very difficult to treat, especially the most malignant type, glioblastoma multiforme (GBM), according to the classification of the World Health Organization (WHO; ref. 1). GBM has a very poor prognosis that has not improved in the past 30 years (1–3). Recently, gliomas have been extensively characterized by genomic and molecular marker analysis, including our work under The Cancer Genome Atlas (TCGA) project (4, 5). These studies have underscored GBM heterogeneity, which may provide new targets for therapy development.

The tumor microenvironment is important for malignant growth, invasion, and escape of the immune surveillance (6). It also serves as a niche for cancer stem cells (CSC) that are largely responsible for tumor resistance to therapy and development of recurrence (6–8). Tumor blood vessels are an integral part of this niche in gliomas and provide structural and functional support to the perivascular CSCs (7–11). These data emphasize the importance of the vascular microenvironment in glioma development and recurrence, and suggest that new therapies can target this niche for inhibiting glioma growth and CSCs (6, 8, 12).

We previously found that GBMs and other tumors overexpressed the vascular basement membrane protein laminin-411 (α4β1γ1), whereas low-grade tumors and normal brain expressed laminin-421 (α4β2γ1). These data suggest a laminin isoform shift (from β2 to β1 chain) during glioma progression (13). Laminin-411, as a progression-related tumor microenvironment marker, may be a promising therapeutic target. Uncovering the molecular ties between laminin-411, angiogenic factors, and signaling pathways that promote tumor angiogenesis and CSC survival may significantly improve brain cancer therapy. In vitro evidence supports the interaction of the laminin-411 α4 chain with the Notch signaling system through the β1 integrin-delta-like 4 (Dll4; Notch ligand) pathway (14–16). Notch-1 is overexpressed in astrocytomas, and Notch-3 is important for glioma invasion (17–19). The Notch receptor family has also been associated with CSCs (20).

In this study, we made several novel observations (1). We documented a correlation of laminin-411 expression levels with glioma grade and CSC markers including Notch-1, Notch-3, CD133, Nestin, and c-Myc in 223 human glioma samples (2). To examine laminin-411 as a therapeutic target, we depleted its α4 and β1 subunits with CRISPR/Cas9 system in human established and patient-derived GBM cell lines (21, 22). When injected into mouse brain, GBM cells lacking laminin-411 developed smaller tumors, and animal survival was significantly increased versus wild-type cells (3). We developed clinically translatable treatment using nanobioconjugate inhibiting laminin-411, where all functional moieties are nontoxic, nonimmunogenic (23), and with a novel chimeric tumor cell–targeting antibody applicable for human treatment. This nanodrug was able to cross blood–brain barrier and prolong survival of animals bearing intracranial GBMs (4). Our in vitro and in vivo data supported the molecular mechanism of laminin-411 action in glioma growth through the signaling cross-talk with Notch system and CSCs, in line with new results on human tumor samples. Nanodrug inhibition or genetic ablation of laminin-411 could thus suppress GBM growth by downregulating laminin-interacting Notch system and CSCs. This study demonstrated a promising new strategy of treatment of deadly brain tumors more efficiently through targeting a critical component of tumor microenvironment, which is largely independent of the heterogeneous genetic mutations in glioblastoma.

Human brain tumor and nontumor brain tissues were obtained from patients treated at Cedars-Sinai Medical Center (Los Angeles, CA). Two hundred and twenty-three human samples were acquired from the Biobank at the Cedars-Sinai Medical Center Department of Pathology and Laboratory Medicine under protocol #3646 approved by the Cedars-Sinai's Institutional Review Board. Written informed consent was obtained from all donors, and the studies were conducted in accordance with the Declaration of Helsinki. Animal studies were approved by Institutional Animal Care and Use Committee protocol #00005289.

Tumor samples included 107 GBMs, 32 grade III, and 46 low-grade (I–II) gliomas (with 4 controls of nontumor brain tissue from trauma patients) and were analyzed for survival and time of recurrence. Twenty-eight GBMs, 6 grade III, 9 grade I–II gliomas, and 8 nontumor brain tissues were evaluated by IHC for “malignant” laminin β1 chain with CSC markers CD133, c-Myc, Notch-1, Notch-3, and Nestin.

Paraffin sections were stained on a BenchMark ULTRA platform using high pH antigen retrieval and the UltraView Universal diaminobenzidine (DAB) detection Kit (Ventana Medical Systems). Frozen sections of human tumors and mouse xenogeneic tumors were stained by double indirect immunofluorescence for CSC markers and laminin β1 chain after acetone or paraformaldehyde fixation. Antibodies are listed in Supplementary Table S1. Images were captured on Leica DM6000 B microscope (Leica Microsystems) in 10 random microscopic fields/section with 40x objective and quantitated with Leica Metamorph (MM AF 1.6) software. Nuclear objects were segregated from the DAPI signal. For CSC markers, the fraction of fluorescently positive cells was quantitated using cell scoring module. To quantitate vessel area, images were auto thresholded, and regions of interest were drawn around the objects, measured, and graphed.

Human GBM lines U87MG and LN229 were obtained from and authenticated by the ATCC using the short tandem repeat method. LN229 cells were 100% identical to the ATCC database. U87MG were 93% identical. Patient-derived primary GBM lines, TS543 and TS576, were maintained in tumor sphere culture as published (22). Normal human brain microvascular endothelial cells (HBMVEC) were from the ATCC. Normal human astrocytes (NHA) were from Lonza. All cells were routinely tested negative for mycoplasma using a kit from Lonza. Human recombinant laminin-411 and laminin-421 used for dish coating were from BioLamina.

Lentiviral CRSISPR/Cas9 system was constructed using LentiCRISPRv2 plasmid (Addgene No. 52961; ref. 24). Guide RNAs (gRNA) were designed with online tool (https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design), and gRNA coding sequence was inserted into LentiCRISPRv2 vector as reported (24). gRNA sequences targeting human laminin α4 gene (hg38_refGene_NM_001105206) and β1 gene (hg38_refGene_NM_002291) were as follows:

• LAMA4 gRNA: GGGCACACATTCTCCCGACA;

• LAMB1 gRNA: CAGGAACCCGAGTTCAGCTA.

Lentiviruses were made by transfecting 293T cells with LentiCRISPRv2 construct with pseudo-viral packaging signals VSV-G and Delta-8.9 as previously reported (25).

Human GBM lines U87MG and LN229 and patient-derived GBM lines TS543 and TS576 (22) were used to generate stable lines with laminin-411 depletion. Cells were coinfected with two lentiviral-CRISPR vectors to knock out laminin-411 α4 and β1 subunits simultaneously. Stable lines were established after 10 days of 2 μg/mL puromycin selection.

The loss of laminin-411 in lentivirus-infected cells was verified by Western blot and DNA sequencing. Exons targeted by CRISPR gRNAs were PCR-amplified from genomic DNA using PfuUltra II Fusion HS DNA polymerase (Agilent) and gel purified for Sanger DNA sequencing. PCR primers for amplification were:

• LAMA4 forward: GGAGGGAAAAAGTTATGTAACAAAGAAG;

• LAMA4 reverse: GCACTTGATTAGCAGTTTGCTCCTAT;

• LAMB1 forward: CCCCCGCTTGTTCGTTTTTTCGG;

• LAMB1 reverse: TCACCTGCAAGTGGCTGACGATACAG.

Animals underwent MRI scanning on a 9.4 T small animal BioSpec 94/20USR scanner (Bruker Biospin MRI GmbH). Mice were placed inside a transmission whole-body coil with a four-channel surface array coil (T11071 V3, Bruker Biospin MRI) positioned over the brain.

Poly(β-L-malic acid) (PMLA) was purified from Physarum polycephalum (25). Morpholino antisense oligonucleotides (AON) 5′-AGCTCAAAGCCATTTCTCCGCTGAC-3′ to laminin α4 and 5′-CTAGCAACTGGAGAAGCCCCATGCC-3′ to laminin β1 chains were from GeneTools. The drug syntheses were optimized, with full characterization and toxicity evaluation (23, 26). A novel recombinant mouse/human chimeric antibody targeting human transferrin receptor 1 (TfR1) with constant human IgG1 regions and variable regions of the murine monoclonal antibody 128.1 was used; it was developed similarly to the previously characterized version with IgG3 constant regions (27).

U87MG or LN229 GBM cells were intracranially inoculated into athymic NCr-nu/nu mice obtained from Taconic as described (28). Mice were treated with PBS or nanobioconjugate P/PEG/LLL (40%)/AON (α4β1; 2.0%)/muTfR (0.15%)/huTfRch (0.15%) with AONs against laminin-411 chains and antibodies for blood–brain barrier (BBB; anti-murine TfR, muTfR) and tumor (chimeric anti-human TfR, huTfRch) targeting. Eight intravenous treatments started 8 days after tumor inoculation using 5 mg/kg AONs on every third day. Mice were euthanized on days 37 and 48 (for U87MG and LN229, respectively) after tumor inoculation, and brains were collected. Tumor volumes were calculated as (length) × (width²)/2 (29). Western blots with tissue lysates were performed as described (28) with GAPDH or β-actin as loading controls. Antibodies are listed in Supplementary Table S1. The blots were scanned and analyzed by a LI-COR Odyssey CLx (LI-COR Biosciences).

U87MG cells were trypsinized, and human-soluble TfR1 was added at 10-fold excess of drugs and incubated for 45 to 60 minutes at 4°C. Fluorescently labeled full and control drugs were added to cell suspensions and incubated at 4°C for 45 to 60 minutes. Analysis was done using flow cytometer LSR Fortessa and FACSDiva software (BD Biosciences).

For tissue accumulation studies, the nanobioconjugate was labeled on tyrosines of attached antibodies with ¹²⁵I using Bolton-Hunter Reagent Kit (Di[¹²⁵I]-BHR, specific activity 577 MBq/mL; Perkin-Elmer). Twenty nude mice were intracranially inoculated with 5 × 10⁵ U87MG GBM cells. In 3 weeks, ¹²⁵I-nanobioconjugate (∼250,000 cpm; specific activity of 32,000 cpm/μg antibody) was injected once into tail vein. Six hours after injection, approximately 18,000 cpm/mg was incorporated in tumor tissue. Mice were euthanized at various time points (1, 2, 6, 12, and 24 hours) after injection. After PBS perfusion, brains were frozen in optimal cutting temperature compound (Sakura Finetek), followed by sectioning and hematoxylin and eosin staining to locate the tumor. After background subtraction, radioactivity was calculated per mg tissue of healthy brain or tumor.

The nanobioconjugate, along with the drug vehicle (PMLA), positive (PHA-M) and negative (PBS) controls, was tested for toxicity (cytokine release). Nanodrug was added in vitro to the whole blood samples from three healthy donors at therapeutic 1X dosage (based on the expected Cmax in human at the human equivalent to the mouse efficacy dose), or 3X dosage. Diluted blood was incubated with controls or nanomaterial. Using quantitative Meso Scale Discovery assay, nine cytokines (TNFα, IFNγ, IL12p70, IL1β, IL2, IL4, IL6, IL8, and IL10) in the donors' blood were simultaneously measured.

The Kaplan–Meier analysis was used for animal survival studies. Patient postdiagnostic survival or recurrence was compared between laminin β1 and β2 groups determined by IHC using the log-rank test (Prism6 program; GraphPad Software). Differences between groups, considering unequal group sizes, were evaluated using the Tukey–Kramer multiple comparison test. The Student t test was used for two groups (treated-untreated) to evaluate differences in the IHC, Western blot, and morphometry assays. Data are presented ± SEM, and P < 0.05 is considered statistically significant.

The expression of laminin-411 and multiple CSC markers was analyzed by IHC in human glioma specimens. Of 107 GBMs, 92% had high levels of laminin β1 versus normal brain tissue, consistent with our previous report (Supplementary Table S2; ref. 13). Anaplastic astrocytoma grade III overexpressed laminin β1 in 67% of cases, whereas anaplastic oligoastrocytoma grade III, in 22%, which correlates with better outcome of these tumors. Only 5%, 12%, and 0% cases in grade II gliomas (astrocytoma, oligodendroglioma, and oligoastrocytoma, respectively) showed laminin β1 expression, and nontumor brain tissues (n = 4) were negative for laminin β1. Median survival of GBM patients (n = 67) with laminin β1 overexpression was 10.0 months, and with a predominant β2 subunit, it was 20.2 months (Supplementary Fig. S1A). Median time to recurrence (n = 63) in GBM patients with laminin β1 was 5.6 months, whereas with laminin β2 it was 9.3 months (Supplementary Fig. S1B).

Laminin β1 chain was found to localize to the vascular basement membrane (BM) in human gliomas (n = 41; Supplementary Fig. S2A, top row). The positive vessel area and laminin β1 staining intensity increased with glioma grade (Supplementary Fig. S2B and S2C; Supplementary Table S2). Because CSCs contribute to glioma progression (20), an association between high expression of laminin-411 and CSC markers was examined. In agreement with previous data (9), tumor cells positive for CSC markers (20) Notch-1, Notch-3, CD133, Nestin, and c-Myc were found close to laminin β1–positive vessels, which was correlated with higher glioma progression grade (Fig. 1).

CSC marker levels were further evaluated (Supplementary Table S3). Notch-1 and Notch-3 were upregulated in high-grade gliomas (III–IV), versus low-grade tumors (I–II) and nontumor brain revealed by IHC (Fig. 1A and B) and morphometric analysis (Supplementary Fig. S3). Similar trends were observed for CD133, Nestin, and c-Myc (Fig. 1C–E; Supplementary Fig. S4), and these CSC markers often colocalized with laminin β1–positive blood vessels.

Extracellular matrix (ECM) contributes to tumor development. As laminin-411 is overexpressed during cancer progression (13), we have tested whether its loss in GBM would impair tumor growth. We disrupted laminin-411 α4 and β1 genes in two established human GBM cell lines and two patient-derived primary GBM lines TS543 and TS576 (22) using CRISPR/Cas9 (Fig. 2A). Controls including Western analysis and genomic sequencing (Fig. 2B and C) confirmed specific elimination of laminin α4 and β1 chains. We then inoculated U87MG and LN229 cells with laminin α4 and β1 double knockout (DKO) along with their WT counterparts intracranially into nude mice (n = 8 in WT groups and n = 10 in DKO groups). After 4 weeks, tumor sizes were measured by MRI (26). Compared with WT tumors, DKO tumors were significantly smaller (Fig. 3A and B). Consistent with imaging results, animals carrying U87MG (moderately invasive) or LN229 (highly invasive) laminin DKO tumors had significantly longer survival than animals with WT tumors (Fig. 3C and D).

Prior studies found an interaction between laminin-411 and Notch pathway in endothelial cells (14–16). To explore this interaction in GBMs, we analyzed intracranial tumors from WT and laminin-411 DKO U87MG cells by Western blot. In DKO tumors, both α4 and β1 expression remained significantly lower than their WT counterparts (Fig. 4). Notch-1, its ligand Jagged1, and another CSC marker, c-Myc, showed significantly lower expression in the laminin-411 DKO tumors (Fig. 4), suggesting that laminin-411 depletion in GBM impaired Notch and other CSC signaling pathways.

The shift of laminin isoforms from 421 (β2-containing) to 411 (β1-containing) was correlated with higher glioma grade and poor patient outcome (Supplementary Figs. S1 and S2). Endothelial laminin-411 interacts with the Notch system through the integrin-Dll4 pathway (15, 16, 30). To determine whether this interaction was functional in normal brain cells and gliomas, we conducted in vitro experiments to test the influence of the ECM on Notch system in NHA, HBMVEC, and cultured human GBM cell lines LN229 and U87MG. NHA and HBMVEC cultured on recombinant “normal” laminin-421 expressed low levels of the signaling molecules β1 integrin, Notch-1, and its ligands Jagged1 and Dll4. However, the expression of these proteins became significantly higher when cells were cultured on the “tumor” laminin-411 (P < 0.05), with the only exception of Jagged1 in NHA (P = 0.05; Fig. 5A and B). These data suggest functional influence of laminin-411 on the expression levels of integrin–Notch pathway members.

The link between laminin-411 and Notch pathway was further examined in cultured GBM cell lines LN229 and U87MG treated with Morpholino AONs to laminin-411 α4 and β1 chains. By Western analysis, combined AONs to laminin-411 α4 and β1 inhibited the expression of their targets compared with the scrambled AON control (Fig. 5C and D). In both cell lines, suppression of laminin-411 led to significantly reduced expression of β1 integrin, Notch-1, and especially the Notch ligands Jagged1 and Dll4 (Fig. 5C and D). Thus, laminin-411 compared with laminin-421 can upregulate the β1 integrin–Notch pathway in normal and malignant brain cells, and its inhibition downregulates this pathway. Our data on the expression of Notch and its ligands agree with juxtacrine/autocrine Notch signaling activation described for gliomas and some other cell types (31, 32).

Increased survival of animals bearing GBM with disrupted laminin-411 led us to develop a therapeutic nanobioconjugate P/PEG/LLL/AON(α4β1)/mu/huTfRch inhibiting laminin-411 by the attached AON. The nanobioconjugate structure, synthesis, characterization, and mode of action are shown (Fig. 6, Supplementary Table S4, and Supplementary Video). This compound was used to treat mice with intracranial xenograft of human GBMs. The nanobioconjugate can cross BBB by endothelial transcytosis through anti-mouse TfR antibody. Tumor cell targeting and internalization are mediated by the attached new chimeric antibody against tumor-overexpressed TfR (ch128.1/IgG1, huTfRch), potentially suitable for clinical use. The functional activity of ch128.1/IgG1, conjugated for the first time together with other components to the PMLA-based nanobiopolymer, was validated by flow cytometry (Supplementary Fig. S5). Specific tumor accumulation in vivo of the full ¹²⁵I-labeled nanobioconjugate was confirmed (Supplementary Fig. S6). Some controls were previously tested and found to be inefficient: (1) nanobioconjugate with AONs to laminin chains but without anti-TfR antibody showed the same animal survival as untreated group (33), and (2) nanobioconjugate with unrelated IgG1 antibody was significantly less accumulated in the GBM than the full nanodrug (34). Biodistribution of the ¹²⁵I-labeled nanobioconjugate showed little accumulation in normal brain within a 24-hour period but a significantly higher signal in the brain tumor (Supplementary Fig. S7).

Multiple systemic treatments of mice bearing intracranial LN229 or U87MG tumors with the nanobioconjugate significantly prolonged survival (Fig. 7A), with dramatic reduction of tumor volume as compared with the PBS treatment group (Fig. 7B). Different survival of untreated U87MG groups in this study may be due to different cell batches and known genetic drift under serum culture conditions (35). Western blot analysis (Fig. 7C and D) and IHC (Supplementary Figs. S8 and S9) confirmed significant decrease of both laminin chains in the nanodrug-treated tumors, and downregulation of integrin β1 and Notch ligand Dll4. In addition, the ratio of cleaved to intact PARP was significantly increased, indicating elevated apoptosis in nanodrug-treated tumors (Fig. 7C and D). In these tumors, IHC and morphometry also revealed a dramatic reduction of laminin β1 and of CSC markers Notch-1, Dll4, integrin β1 (Fig. 7D), Notch-3, CD133, Nestin, and c-Myc versus PBS control (Supplementary Figs. S8 and S9). These data correlated well with in vitro results (Fig. 5). In line with these findings, in two lines of patient-derived primary GBM cells TS543 and TS576 (22), the expression levels of Notch-1 and Jagged1 were correlated with the levels of laminin-411 expression, and when laminin-411 was depleted by CRISPR/Cas9, both these lines exhibited substantial reduction in the expression of Notch-1 and Jagged1 (Fig. 2B; Supplementary Fig. S10).

The nanobioconjugate was tested in cytokine induction assays, using human blood from 3 healthy donors, along with the drug vehicle (PMLA), positive (PHA-M) and negative (PBS) controls. A therapeutic 1X concentration and even 3X elevated concentration of the nanodrug did not significantly induce any of the nine cytokines in the donors' blood (n = 3, Supplementary Table S5), except for IL8 in the 3X elevated dose group. However, this IL8 level was still 40-fold lower than in the positive control group. Therefore, the nanobioconjugate showed virtually no toxicity.

Laminin-411 is a vascular wall marker overexpressed in glioblastomas (36–38). In this study, we have established a strong correlation of laminin-411 overexpression with human glioma tumor grade, and with shorter survival and time to recurrence in GBMs. We then examined whether inhibiting laminin-411 in animal models would affect survival. Using CRISPR/Cas9 technology, we blocked laminin-411 expression in two human GBM cell lines and showed that mice bearing tumors with laminin-411 knockout exhibited slower tumor growth and better survival versus mice carrying WT tumors. Consistent with these findings, significantly improved survival and reduced tumor burden were observed in nude mice with intracranial human GBMs treated with a nanobioconjugate blocking the expression of laminin-411 α4 and β1 chains. Our treatments are also supposed to deplete some other laminin isoforms. However, the major change in GBMs concerns upregulation of laminin-411 (13, 38, 39), and we thus believe that the main effect was due to laminin-411 blocking.

Our study newly established a functional link between laminin-411 and Notch pathway in both normal and malignant brain cells in vitro, consistent with signaling from laminin-411 via its binding β1 integrin to the Dll4-Notch pathway (Figs. 5 and 6). Accordingly, treatment of mice bearing GBMs with nanobioconjugate inhibiting laminin-411 prolonged animal survival with suppression of Notch family members Dll4, Notch-1, and Notch-3 in the residual tumors (Fig. 7; Supplementary Figs. S8 and S9). Laminins also contribute to cell adhesion and migration. Laminin-411 can facilitate GBM cell invasion (39), and its expression levels in patient GBMs correlate with glioma aggressiveness (Supplementary Table S2). Our data suggest an interplay between the effects of laminin-411 on glioma migration and invasion and on Notch signaling through interactions with laminin-binding integrin(s) containing β1 chain. Supporting this hypothesis, adhesion of glioma cells to laminin-411 increased the expression of both Notch system and β1-containing integrin (Fig. 5). Conversely, depletion of laminin-411 with CRISPR/Cas9 or a nanobioconjugate suppressed GBM growth and survival with downregulation of Notch system and β1 integrin.

Along with Notch, other CSC markers (20, 40–42) including Nestin, CD133, and c-Myc were dramatically reduced in GBMs upon laminin-411 inhibition. These are common markers of neural stem cells and CSCs, and some of them (Nestin, Notch-1, Notch-3, and their ligands) have increased expression in gliomas (17–20). c-Myc is often activated in various tumor types including gliomas (42), and is important for cell proliferation, cell-cycle progression, angiogenesis, and tumor response to immunotherapy (43).

Brain tumor CSCs reside in a perivascular niche (9) similar to neural stem cells (44, 45). Our work demonstrated that inhibition of vascular BM component laminin-411, which is produced by tumor cells like many tumor ECM components (46), disrupts the perivascular CSC niche and negatively affects CSCs, and may enhance the efficacy of glioma therapy. Overall, blocking laminin-411–Notch cross-talk by our nanobioconjugate could become a novel glioblastoma treatment independent of genomic changes associated with tumor progression.

Notably, our experimental approach using CRISPR/Cas9 to disrupt the expression of both laminin α4 and β1 subunits demonstrated high efficiency in both established GBM cell lines as well as the primary patient-derived GBM cells (Fig. 2B and C). Future development of CRISPR/Cas9-based nanodrug to regulate the expression of complex ECM components in tumor microenvironment might provide us an even more convenient and powerful approach, owing to the ease in multiplex genome engineering with this technology (47, 48).

A clinically relevant advantage of the PMLA-based nanobioconjugate is its lack of toxicity despite of moieties potentially capable of inducing acute cytokine release in the blood (cytokine storm; ref. 49). In the ex vivo human blood toxicity assay, the nanobioconjugate did not induce acute cytokine release. A very similar nanodrug also showed no toxicity in mice after repeated i.v. injections using the complete blood count and chemistry and metabolic panel assays (50).

J.D. Rudnick reports receiving honoraria from the speakers' bureau of Novocure. M.L. Penichet is CSO at, has an ownership interest (including stock, patents, etc.) in, and is a consultant/advisory board member for Klyss Biotech, Inc. E. Holler reports receiving honoraria from the speakers' bureau of Arrogene and has an ownership interest (including stock, patents, etc.) in shares of Arrogene. A.V. Ljubimov is VP for research at and has an ownership interest (including stock, patents, etc.) in Arrogene, Inc. J.Y. Ljubimova is CSO at and has an ownership interest (including stock, patents, etc.) in Arrogene, Inc. No potential conflicts of interest were disclosed by the other authors.

Conception and design: T. Sun, D. Li, A.V. Lyubimov, M.L. Penichet, E. Holler, A.V. Ljubimov, J.Y. Ljubimova

Development of methodology: T. Sun, D. Li, S.I. Bannykh, V. Falahatian, Y.L. Chen, M.L. Penichet, E. Holler, J.Y. Ljubimova

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T. Sun, R. Patil, A. Galstyan, D. Klymyshyn, H. Ding, A. Chesnokova, W.K. Cavenee, V.A. Ljubimov, E.S. Shatalova, S. Wagner, D. Li, A.N. Mamelak, S.I. Bannykh, C.G. Patil, J.D. Rudnick, J. Hu, A. Rekechenetskiy, Y.L. Chen, K.L. Black, J.Y. Ljubimova

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Sun, R. Patil, A. Galstyan, A. Chesnokova, W.K. Cavenee, V.A. Ljubimov, E.S. Shatalova, S.I. Bannykh, V. Falahatian, A.V. Lyubimov, Y.L. Chen, A.V. Ljubimov, J.Y. Ljubimova

Writing, review, and/or revision of the manuscript: T. Sun, R. Patil, F.B. Furnari, V.A. Ljubimov, D. Li, S.I. Bannykh, C.G. Patil, J.D. Rudnick, A.V. Lyubimov, L.S. Leoh, T.R. Daniels-Wells, M.L. Penichet, A.V. Ljubimov, J.Y. Ljubimova

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D. Klymyshyn, A. Chesnokova, F.B. Furnari, E.S. Shatalova, A.N. Mamelak, J.Y. Ljubimova

Study supervision: J.D. Rudnick, E. Holler, A.V. Ljubimov, J.Y. Ljubimova

Other (nanobioconjugate synthesis and characterization): Z.B. Grodzinski

Other (developed antibody and designed experiments using the antibody): L.S. Leoh

Other (together with M.L. Penichet and L.S. Leoh, developed the ch128.1/IgG1 antibody, and contributed to the design of experiments using this antibody as well as editing of the article): T.R. Daniels-Wells

The authors thank Gene Arvan (Vir8 Studio Inc.) for video art representing the treatment technology and Dr. Pallavi Gangalum for expert technical assistance. We are grateful to late Dr. Randa Alsabeh who provided very important clinical evaluation of human glioma samples.

This work was supported by the following grants: U01 CA151815 (J.Y. Ljubimova), R01 CA188743 (J.Y. Ljubimova), R01 CA206220 (J.Y. Ljubimova), R01 EY013431 (A.V. Ljubimov), R01 CA209921 (E. Holler), R01 CA196266 (M.L. Penichet), and Health Effects of Air Pollution Foundation Agreement No. BTAP011 (K.L. Black).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.